Cathérine Reenaers - Concepedia

Author

Cathérine Reenaers

Also Known As

C REENAERS, C Reenaers, C Reenaers Dr, C. Reenaers, Catherine REENAERS, Catherine Reenaers, Catherine, Reenaers, Cathérine Reenaers, Edouard Louis, R Catherine

168

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

University of Liège Centre Hospitalier Universitaire de Liège Hôpital Saint-Antoine Sorbonne Université Université de Lorraine

About

Cathérine Reenaers is an author at University of Liège specializing in medicine, gastroenterology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	12	762
2	Gastroenterology	7	9	518
3	Epidemiology	2	3	89
4	Public Health	1	2	74
5	Hepatology	1	1	15

Cathérine Reenaers

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment Hannah Gordon, Silvia Minozzi, Uri Kopylov, Journal of Crohn s and Colitis	2024	240
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease Yukihide Momozawa, Myriam Mni, Kayo Nakamura, Nature Genetics InflammationImmunologyPathologyAutoimmunityImmune System	2010	186
Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohnʼs disease with normal C-reactive protein serum level Marie-Armelle Denis, Cathérine Reenaers, Fernand Fontaine, Inflammatory Bowel Diseases	2007	117
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment Michel Adamina, Silvia Minozzi, Janindra Warusavitarne, Journal of Crohn s and Colitis GastroenterologyVisceral SurgerySurgeryUpper Gastrointestinal SurgeryEcco Guidelines	2024	114
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients Filip Baert, E Glorieus, Cathérine Reenaers, Journal of Crohn s and Colitis	2012	110
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission Cathérine Reenaers, Jean–Yves Mary, Maria Nachury, Clinical Gastroenterology and Hepatology GastroenterologyOutcomes ResearchClinical GastroenterologySustained RemissionUlcerative Colitis	2017	91
The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab Uri Kopylov, Gerassimos J. Mantzaris, K.H. Katsanos, Alimentary Pharmacology & Therapeutics	2010	89
Does co‐treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Cathérine Reenaers, Édouard Louis, Jacques Bélaïche, Alimentary Pharmacology & Therapeutics	2012	85
Increased expression of receptor activator of NF-<i>κ</i>B ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients Nathalie Franchimont, Cathérine Reenaers, Cécile Lambert, Clinical & Experimental Immunology	2004	74
Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases Diane Lorenzo, Frédérique Maire, Carmen Stefănescu, Clinical Gastroenterology and Hepatology Autoimmune DiseaseImmunologyGastroenterologyAutoimmunityAutoantibodies	2017	71

Page 1